Retraction Note: Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials

Affiliations

¹ MAPS Public Benefit Corporations, 1115 Mission St., Santa Cruz, CA, 95060, USA. Ilsa@mapsbcorp.com.
² MAPS Public Benefit Corporations, 1115 Mission St., Santa Cruz, CA, 95060, USA.
³ Stanford School of Medicine, Stanford University, Stanford, CA, USA.
⁴ Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, USA.
⁵ Medical University of South Carolina, Charleston, SC, USA.

Lisa Jerome et al. Psychopharmacology (Berl). 2024 Nov.

. 2024 Nov;241(11):2407.

doi: 10.1007/s00213-024-06665-y.

¹ MAPS Public Benefit Corporations, 1115 Mission St., Santa Cruz, CA, 95060, USA. Ilsa@mapsbcorp.com.
² MAPS Public Benefit Corporations, 1115 Mission St., Santa Cruz, CA, 95060, USA.
³ Stanford School of Medicine, Stanford University, Stanford, CA, USA.
⁴ Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, USA.
⁵ Medical University of South Carolina, Charleston, SC, USA.

No abstract available

Retraction of

Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Jerome L, et al. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. Psychopharmacology (Berl). 2020. Retraction in: Psychopharmacology (Berl). 2024 Nov;241(11):2407. doi: 10.1007/s00213-024-06665-y. PMID: 32500209 Free PMC article. Retracted. Clinical Trial.